It's going to take 3.5 billion image agent varieties

Pharmaceutical Network November 25th, recently, the official website of the State Drug Administration shows that Zhengda Tianqing Pharmaceutical Group to imitate the 4 categories of iodized kesha alcohol injection into the administrative approval stage, is expected to be approved in recent days and as reviewed.
is an X-ray spectral agent, and in 2019, China's public medical institutions will have sales of more than 3.5 billion yuan.
Iodine kesalol, developed by GE Healthcare AS (General Electric), is the only X-ray diagnostic contrast agent with blood seepage, with high heart safety, strong kidney tolerance, good patient comfort, less interference with cardiopulmonary circulation and other advantages, in the nerve and cardiovascular system, chest, abdomen, pelvic cavity and other organ lesions in the examination to improve the detection rate and diagnosis of the role of identification, by many clinical guidelines and expert consensus at home and abroad.
meters of intranet data show that in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal iodized kesha alcohol injection sales of more than 3.5 billion yuan.
, Hengrui Pharmaceuticals has a market share of 50.48 per cent and General Electric 34.14 per cent.
At present, six pharmaceutical companies in the domestic market have been approved to produce iodized kesha alcohol injections, respectively, General Electric, Hengrui Pharmaceuticals, Yangzijiang Pharmaceutical Group, Beiland Pharmaceuticals, Nanjing Zhengtianqing, Staili.
, so far, iodized kesha alcohol injection evaluation enterprises only Staly.
Iodine kesal injections to be approved enterprise source: Mi net one-click retrieval of minenet data show that Harbin Triple Pharmaceuticals according to imitation 6 categories of submitted iodized keshaol injection application in the review and approval;
source: MiNet Database, NMPA